文献速递白血病

抑制泛素特异性蛋白酶7使急性髓系白血病对化疗敏感

Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
PubMed 文献 · Leukemia · 2020-05-23

该研究通过体外和体内实验证明抑制去泛素化酶USP7可减少急性髓系白血病细胞增殖、阻断DNA复制并增加细胞死亡;转录组分析显示USP7基因特征在复发患者及阿糖胞苷处理的PDX残留原始细胞中富集,且USP7抑制与阿糖胞苷协同杀伤高USP7水平白血病细胞。

要点

  • 抑制USP7在体外和体内显著减少急性髓系白血病细胞增殖并增加细胞死亡。
  • USP7基因特征在复发急性髓系白血病患者及阿糖胞苷处理的PDX残留原始细胞中富集。
  • USP7抑制与阿糖胞苷协同杀伤高USP7水平的急性髓系白血病细胞系和原代细胞。

核心结论

  • USP7既是急性髓系白血病化疗耐药的标志物,也是克服治疗耐药的潜在治疗靶点。

研究设计与样本

  • 研究采用体外和体内实验、转录组数据集分析、单细胞分析及患者来源异种移植(PDX)模型。

主要发现

  • 抑制USP7在体外和体内显著减少急性髓系白血病细胞增殖,阻断DNA复制进展并增加细胞死亡。
  • USP7基因特征在复发急性髓系白血病患者细胞及经临床相关剂量阿糖胞苷处理的PDX模型残留原始细胞中高度富集。
  • 单细胞分析显示,复发时负责复发的预先存在亚群的基因特征在高USP7水平患者转录组中富集。
  • USP7与CHK1蛋白相互作用并调节其水平和功能。
  • USP7抑制与阿糖胞苷协同杀伤高USP7水平的急性髓系白血病细胞系和患者原代细胞。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance of acute myeloid leukemia (AML) to therapeutic agents is frequent. Consequently, the mechanisms leading to this resistance must be understood and addressed. In this paper, we demonstrate that inhibition of deubiquitinylase USP7 significantly reduces cell proliferation in vitro and in vivo, blocks DNA replication progression and increases cell death in AML. Transcriptomic dataset analyses reveal that a USP7 gene signature is highly enriched in cells from AML patients at relapse, as well as in residual blasts from patient-derived xenograft (PDX) models treated with clinically relevant doses of cytarabine, which indicates a relationship between USP7 expression and resistance to therapy. Accordingly, single-cell analysis of AML patient samples at relapse versus at diagnosis showed that a gene signature of the pre-existing subpopulation responsible for relapse is enriched in transcriptomes of patients with a high USP7 level. Furthermore, we found that USP7 interacts and modulates CHK1 protein levels and functions in AML. Finally, we demonstrated that USP7 inhibition acts in synergy with cytarabine to kill AML cell lines and primary cells of patients with high USP7 levels. Altogether, these data demonstrate that USP7 is both a marker of resistance to chemotherapy and a potential therapeutic target in overcoming resistance to treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cartel M, Mouchel PL, Gotanègre M, et al. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy. Leukemia. 2020. PMID: 32447346. doi:10.1038/s41375-020-0878-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。